Skip to main content

Tweets

What are the RFs for progression of Pso to PsA? 🔸PsO disease severity - 3.2x risk —>PsA 🔸Phenotype - nail involvement 🔸Obesity - 6x higher risk of developing PsA 🔸MSK symptoms - arthralgia & heel pain #ACR25 @RheumNow https://t.co/UPXuxBPyKI
4 days 9 hours ago
The severity of skin psoriasis increases the risk of psoriatic arthritis. Scher J @RheumNow #ACR25 https://t.co/EI0ACWACHy
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
4 days 9 hours ago
SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease SGLT-2 inhibitors offer benefits beyond glycemic control, such as cardioprotective and nephroprotective effects, and modest weight loss. A recent study also suggests they may have immunomodulatory effects and https://t.co/grsgHFQic5
Dr. John Cush @RheumNow ( View Tweet )
4 days 10 hours ago
Is tocilizumab equally effective in ischemic vs. non-ischemic GCA? Ischemic = vision, jaw claudication, or CVA Remission at 6 mo higher in non-ischemic group then with equalization at month 12 No major difference in GCs at month 12 @RheumNow #ACR25 #Abst0739 https://t.co/OeYggSQYx8
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
4 days 10 hours ago
RA may age the immune system by nearly two decades. IgG glycome profiles showed inflammatory aging even in early RA, tied to low fitness & high inflammation. Improving muscle & fitness may help reverse this biologic clock. @RheumNow #ACR25 Abstract #0835

Jiha Lee @JihaRheum ( View Tweet )

4 days 10 hours ago
We need more biomarkers in GCA - what about fibrinogen? Miller et al retrospectively compared CRP, ESR, and fibrinogen at different points in GCA dx Fibrinogen (and ESR/CRP) only helpful prior to initiation GC with comparable performance @RheumNow #ACR25 Abst #0750 https://t.co/q5gFxDMnTy
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
4 days 10 hours ago
Can tissue give us an underlying diagnosis in aortitis? Dr. Kermani breaks down the autoimmune differential based on histopathology @RheumNow #ACR25 https://t.co/twcH021dxS
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
4 days 10 hours ago
Abstract 0842 💡 Urinary biomarkers as the next frontier for monitoring lupus nephritis activity 🔹 Proteinuria didn’t track w/ histologic activity 🔹 IL-16 & sCD163 correlated at baseline only 🔹 Urinary Tenascin C & BAFF correlated w/ activity at 1 yr @RheumNow #ACR25

Akhil Sood MD, MS @AkhilSoodMD ( View Tweet )

4 days 10 hours ago
2 year extension data from SELECT-GCA: Patients in remission who remained on upadacitinib 15mg daily after 1 year had 90% reduced risk of flare compared to those who switched to placebo Higher rates zoster, CK elevation in UPA group #ACR25 @RheumNow #ACRBest https://t.co/jf8Dh2wCBj
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
4 days 10 hours ago
The differential diagnosis for CNS vasculitis is BROAD. Keep in mind it’s mimics @RheumNow #ACR2025 https://t.co/ASWr6zm5eQ
Gabriela Martinez Zayas, MD @MartinezZayasMd ( View Tweet )
4 days 10 hours ago
Social media based outreach to pts for research Out of 617,207 users engaged, 6 filled the contact form Based on this social media (knowing also promotion costs) might not be the best strategy to recruit for clinical trials @RheumNow #ACR25 https://t.co/qCH9WXyTD7

Aurelie Najm @AurelieRheumo ( View Tweet )

4 days 10 hours ago
💊 SGLT2i vs GLP-1 in Lupus Nephritis TriNetX evaluating the impact of GLP-1 agonists vs SGLT-2 inhibitors on outcomes of lupus nephritis 📊 GLP-1 use linked to better renal & CV outcomes in LN including: ⬇️ CKD progression ⬇️ Mortality ⬇️ Acute MI @RheumNow #ACR25 https://t.co/v4LgKFDt68
Akhil Sood MD, MS @AkhilSoodMD ( View Tweet )
4 days 10 hours ago
×